Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer by unknown
SYSTEMATIC REVIEW
Unremarked or Unperformed? Systematic Review on Reporting
of Validation Efforts of Health Economic Decision Models
in Seasonal Influenza and Early Breast Cancer
Pieter T. de Boer1 • Geert W. J. Frederix2 • Talitha L. Feenstra3,4 •
Pepijn Vemer1,3
Published online: 29 April 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Background Transparent reporting of validation efforts of
health economic models give stakeholders better insight
into the credibility of model outcomes. In this study we
reviewed recently published studies on seasonal influenza
and early breast cancer in order to gain insight into the
reporting of model validation efforts in the overall health
economic literature.
Methods A literature search was performed in Pubmed
and Embase to retrieve health economic modelling studies
published between 2008 and 2014. Reporting on model
validation was evaluated by checking for the word
validation, and by using AdViSHE (Assessment of the
Validation Status of Health Economic decision models), a
tool containing a structured list of relevant items for vali-
dation. Additionally, we contacted corresponding authors
to ask whether more validation efforts were performed
other than those reported in the manuscripts.
Results A total of 53 studies on seasonal influenza and 41
studies on early breast cancer were included in our review.
The word validation was used in 16 studies (30 %) on
seasonal influenza and 23 studies (56 %) on early breast
cancer; however, in a minority of studies, this referred to a
model validation technique. Fifty-seven percent of seasonal
influenza studies and 71 % of early breast cancer studies
reported one or more validation techniques. Cross-valida-
tion of study outcomes was found most often. A limited
number of studies reported on model validation efforts,
although good examples were identified. Author comments
indicated that more validation techniques were performed
than those reported in the manuscripts.
Conclusions Although validation is deemed important by
many researchers, this is not reflected in the reporting
habits of health economic modelling studies. Systematic
reporting of validation efforts would be desirable to further
enhance decision makers’ confidence in health economic
models and their outcomes.
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Key Points for Decision Makers
All stakeholders have a vested interest in a high
validation status of health economic models since
they play an important role in the economic
evaluation of therapeutic interventions. Transparent
reporting of validation efforts and their outcomes
will allow stakeholders to make their own judgment
of a model’s validation status.
Only a limited number of studies reported on
validation efforts, although good examples were
identified. To further increase transparency, more
explicit and structured attention to the reporting of
validation efforts by authors and journals seems
worthwhile.
1 Introduction
Health economic decision analytic models play an impor-
tant role in the economic evaluation of therapeutic inter-
ventions [1]. Since policy decisions are influenced by the
results of such models, all stakeholders have a vested
interest in a high validation status of these models.
Transparent reporting of validation efforts and their out-
comes will give the stakeholder better insight into the
model’s credibility (is the model scientifically sound?),
salience (is the model applicable within the context?) and
legitimacy (are all stakeholder concerns, values and views
included properly?) [2, 3]. Proper information regarding
these aspects allows stakeholders to make their own
judgement of the models’ validation status.
Several systematic reviews of health economic evalua-
tions in different disease areas indicated that little was
reported on model validation [4–10]; however, most of
these reviews were not focused on the general quality of
modelling aspects and contained little details on model
validation performances. Only one review, focusing on
interventions on cardiovascular diseases, provided a clear
overview on which part of the included studies reported on
model validation tests distinguishing model validation
techniques according to the International Society for
Pharmacoeconomics and Outcomes Research–Society for
Medical Decision Making (ISPOR–SMDM) guidelines [9].
However, modelling evaluation processes might vary
between different disease areas, therefore more studies
assessing model validation efforts are needed.
In this study we aimed to systematically review the
reporting of validation efforts of recently published health
economic decision models, explicitly distinguishing
between different validation techniques. For this purpose,
we chose two example diseases, namely seasonal influenza
(SI) and early breast cancer (EBC). These two diseases are
well-defined and by choosing both a communicable dis-
ease, which is often modelled using dynamic models [11],
and a non-communicable disease, which is often modelled
using static models, we expected to cover a wide range of
model types [1]. This should provide a good overview of
the current standard in the reporting of validation efforts in
the health economic literature.
Since validation is an integral part of the modelling
process (see, for example, Fig. 2 in Sargent [12]), low
reporting of validation efforts does not have to mean that
they were not performed. For instance, impromptu check-
ing of bits of computer code while coding may not always
be reported. In order to gain insight into the discrepancy
between the performance and reporting of validation
efforts, we also reached out to the corresponding author of
each of the included papers in this review for comments.
2 Methods
2.1 Search Strategy and Study Selection
We searched the PubMed and Embase databases to identify
studies focusing on the health economic evaluations of SI
and EBC. The full search strings for both diseases can be
found in Appendix 1 and contained free-text searching
terms as well as exploded (Medical Subject Heading
[MeSH]) terms. For both disease areas, the health eco-
nomic evaluations had to meet the following criteria: (1)
published in peer reviewed journals from January 2008 to
December 2014; (2) presented results of costs as well as
health effects; and (3) used a computer simulation model to
generate these results. We also screened reference lists of
selected articles. Review papers, meta-analyses, letters and
non-full-text such as abstracts were excluded, and we
restricted our selection to the English language. For SI,
studies focusing only on pandemic influenza were exclu-
ded, as well as studies analyzing interventions against
multiple infectious diseases without showing separated
results for SI. For EBC, we excluded studies on metastatic
breast cancer, breast cancer screening and diagnostic sys-
tems to stage breast cancer.
2.2 Study Characteristics
General characteristics of the studies extracted included
year of publication, country, income level of the country
according to the classification of the World Bank [13],
funding source, type of intervention, type of evaluation and
model type. For SI, studies that incorporated disease
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transmission dynamics (i.e. from carrier/infected to a sus-
ceptible individual), or used discrete event simulation were
categorised as dynamic models. In all other cases, the
model was categorised as static.
2.3 Reporting of Model Validation Efforts
In this study, we defined validation as the act of evaluating
whether a model is a proper and sufficient representation of
the system it is intended to represent in view of an appli-
cation, where ‘proper’ was defined as ‘‘the model is in
accordance with what is known about the system’’ and
‘sufficient’ was defined as ‘‘the results can serve as a solid
basis for decision making’’ [14]. We first searched the
publication’s text and appendices for the word validation
and its conjugate forms (valid*, verif*). When present, we
reported the context in which the word was used. Then, the
reporting of model validation efforts were systematically
assessed, using the outline presented in the validation-
assessment tool AdViSHE (Assessment of the Validation
Status of Health Economic decision models) [15]. This tool
was designed to provide model users with structured
information regarding the validation status of health eco-
nomic decision models, and therefore enables systematic
extraction of the reporting of model validation efforts. An
added advantage of this tool is that it explicitly presents
clear definitions of validation techniques since there is
little, if any, consensus on terminology in the validation
literature [16]. An abbreviated form of the AdViSHE tool
is shown in Table 1 and includes five validation categories,
i.e. validation of the conceptual model (A, the theories and
assumptions underlying the model concepts, and the
model’s structure and causal relationships), input data (B,
available input data and data transformations), comput-
erised model (C, implemented software program, including
code, mathematical calculations and implementation of the
conceptual model), and operational model (D, behaviour of
the model outcomes). Remaining validation techniques,
such as, for instance, double programming, are assigned to
category E. Assessment of studies on validation reporting
was performed by two of the authors (PdB and PV for
influenza, and PdB and GF for EBC) separately. After
comparing results, differences between the two authors
were resolved in a consensus meeting. Examples of each
validation technique found were collected and presented.
2.4 Comments from Authors
The corresponding authors of the included studies were
contacted by email in August 2015, followed by a reminder
in November 2015. In this email, we explained the aim of
our study, provided details of the corresponding author’s
Table 1 Validation aspects included in the AdViSHE validation status assessment tool [15]
Validation categories Subcategory Questions
(A) Conceptual
model
A1 Face validity Have experts been asked to judge the appropriateness of the conceptual model?
A2 Cross validity Has this model been compared with other conceptual models found in the literature or clinical
textbooks?
(B) Input data B1 Face validity Have experts been asked to judge the appropriateness of the input data?
B2 Model fit When input parameters are based on regression models, have statistical tests been performed?
(C) Computerised
model
C1 External review Has the computerised model been examined by modelling experts?
C2 Extreme value
testing
Has the model been run for specific, extreme sets of parameter values in order to detect any
coding errors?
C3 Testing of traces Have patients been tracked through the model to determine whether its logic is correct?
C4 Unit testing Have individual submodules of the computerised model been tested?
(D) Operational
model
D1 Face validity Have experts been asked to judge the appropriateness of the model outcomes?
D2 Cross validity Have the model outcomes been compared with the outcomes of other models that address
similar problems?
D3 Alternative input Have the model outcomes been compared with the outcomes obtained when using alternative
input data?
D4 Empirical data Have the model outcomes been compared with empirical data?
(A) Comparison against the data sources on which the model is based (dependent validation)
(B) Comparison against a data source that was not used to build the model (independent
validation)
(E) Other techniques – Have any other validation techniques been performed?
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paper that was included in our review, and enquired whe-
ther authors had performed validation efforts other than
those reported in their manuscript. To provide help on
validation techniques that could have been performed, we
attached the AdViSHE tool to this email. Any answers
from the authors were reported.
3 Results
3.1 Study Selection
The searches resulted in 53 SI studies [17–70] and 41 EBC
studies [71–111] that were eligible for inclusion in our
review. More details on the study selection process are
shown in Fig. 1a, b.
3.2 Study Characteristics
General characteristics of the included studies are shown in
Table 2. For both disease areas, most studies were per-
formed in countries in North America, followed by coun-
tries in Europe and Asia. Studies were predominantly
performed for high-income countries, although we also
found studies for middle-income countries such as China,
Taiwan and Argentina (SI), and China, Brazil, Colombia
and Iran (EBC). We found no studies for low-income
countries.
All SI studies analyzed pharmaceutical interventions,
i.e. influenza vaccines or antiviral drugs. One study addi-
tionally assessed non-pharmaceutical mitigation strategies,
including ventilation, face masks, hand washing and
ultraviolet irradiation [21]. For EBC, antineoplastic drugs
were predominantly studied, although we also included
four studies on radiation or surgery treatments [72, 84, 100,
111].
SI was analyzed using static models in 43 (81 %) of the
studies, mostly a decision tree model (36, 68 %) or a state
transition model with Markov properties [‘Markov model’]
(6, 11 %). One study used a multicohort model, in which
cohorts of different ages were simultaneously followed
over their lifetimes [64]. A total of eight studies (15 %)
used a dynamic transmission model, with all compart-
mental models using an SIR structure [17, 21, 25, 28, 29,
50, 51, 54]. Such models divide the population between
susceptible (S), infected (I) and recovered (R), and include
a (often age-stratified) mixing pattern between different
groups. One study did not elaborate on model structure
[57], and another study called the model ‘spreadsheet
based’, with no further information on model type or
structure [70]. Thirty-seven EBC studies (90 %) used a
Markov model [71–83, 85–95, 97–102, 104–107, 109–
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Fig. 1 a Seasonal influenza literature search. b Early breast cancer literature search
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111], one study used a decision tree [96], and one study
used a semi-Markov model [84]. Two studies did not
provide information on model type, but either defined the
model as a ‘decision analytic model’ [108] or stated that
‘the model took a state-transition approach’ [103].
Within the study selection process, multiple studies had
the same first author. For SI, one author conducted ten
studies [32–42], two authors conducted three studies [49–
51, 67–69] and three authors conducted two studies [23, 24,
55, 56, 60, 61], while for EBC, one author conducted three
studies [93–95] and three authors conducted two studies
[80, 81, 103, 104, 109, 110].
3.3 Model Validation
3.3.1 Free-Text Search
For SI, the word ‘validation’ or its conjugates was found in
16 studies (30 %). The context in which ‘validation’ was
used diverged widely. Three studies did not use validation
in a model validation context [27, 52, 53]; two studies
mentioned that the evidence level of some input data was
low and not validated [47, 57]; one study stated that
picking a starting date for the simulation between two
influenza seasons would be useful ‘‘to demonstrate model
validity’’, but did not specify how this was the case [48];
two studies used the word ‘validation’ in a context that
might be linked to a validation technique, but did not
provide information on which parts of the model were
validated, by whom, or which techniques were used [44,
64]; and three studies stated that a previously validated
model was used, without stating whether the model would
be valid for the new purpose [56, 60, 61]. Consulting the
prior publications these studies were based on did not
provide further clarification on validation efforts per-
formed. In seven studies (13 %), the word ‘validation’ was
used in such a way that we were able to link this directly to
a validation technique [17, 20, 25, 30, 48, 62, 64]; these are
discussed in the next paragraph.
For EBC, 23 studies (56 %) reported the word ‘valida-
tion’ or its conjugate forms, also in various contexts. In
four studies we found ‘validation’ was not related to vali-
dation techniques of the health economic model [73, 78,
101, 106]. A fifth study debated ‘‘[t]he validity of the
assumption of differences in effectiveness with letrozole
and anastrozole’’ [91], while a sixth study mentioned that
‘‘[n]o relevant cost and/or utility data were identified
against which the model’s outputs could be validated’’
[88]. In two studies by the same first author it was stated
that that ‘‘[t]he validity of the model is presented using cost
effectiveness-acceptance curves’’ [93, 95]. A total of 16
(39 %) of the included EBC studies used the word ‘vali-
dation’ in a context linked to a model validation technique,
which will be addressed below [71, 72, 74, 76, 77, 80, 82,
84, 85, 87, 88, 92, 100, 104, 109, 110].
3.3.2 Validation Techniques
We identified 30 studies (57 %) on SI that reported one or
more validation techniques, and 28 (68 %) EBC studies.
Two or more validation techniques were found in five
Table 2 General statistics of the studies included in the review
Study characteristic Seasonal influenza Early breast cancer
N % of total N % of total
Total studies included 53 100 41 100
Region
Europe 8 15 14 34
North America 34 64 16 39
Asia 6 11 7 17
South America 1 2 3 7
Australia 4 8 1 2
Income level
High 50 94 35 85
Middle 3 6 6 15
Low 0 0 0 0
Funding
Public health sources 28 53 17 41
Industry 15 28 17 41
No external funding 2 4 3 7
Not stated 7 13 4 10
Type of interventiona
Pharmaceutical-related
Vaccine 45 85 – –
Drug 8 15 37 90
Non-pharmaceutical related
Personal protection 1 2 – –
Radiation – – 3 7
Surgical intervention – – 1 2
Type of evaluation
Cost-benefit 6 11 0 0
Cost-effectiveness 6 11 4 10
Cost-utility 41 77 37 90
Model type
Dynamic
Compartmental model 8 15 0 0
Semi-Markov 0 0 1 2
Static
Decision tree 36 68 1 2
Multicohort 1 2 0 0
Markov 6 11 37 90
Not stated 2 4 2 5
a Multiple interventions might be studied in one study
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studies (9 %) of SI and 15 studies (37 %) on EBC. Fig-
ure 2 shows the model validation performance stratified by
(sub)category.
Five studies reported on validation of the conceptual
model (category A). Four EBC studies reported on face
validity of (part of) the conceptual model [74, 85, 88, 92]
(A1). For example, Au et al. [74] reported that ‘‘validation
of [treatment] strategies were achieved by consensus of a
Canadian panel of breast cancer oncologists’’, including the
identities of the concerned oncologists. Hall et al. [85]
reported that ‘‘[t]he structure of the model was developed
by consensus between clinical experts, health economists
and medical statisticians’’, and reported the background as
well as selection procedure. This study also performed
cross-validation of the conceptual model (A2) by per-
forming a systematic review to identify all previously
published models of the same intervention and subse-
quently comparing the conceptual model. We also found
cross-validation of the conceptual model in one other study
on EBC [88] and one study on SI [47].
Reporting on validation of input data (category B) was
found in nine studies. Face validity (B1) was described in
two SI studies [20, 62]. For example, Tarride et al. [62]
mentioned that ‘‘144 Canadian physicians were surveyed to
validate [complication rate] estimates for children aged
2-5 years old’’. Testing of the model fit (B2) was addressed
in one study on SI [30] and six studies on EBC [77, 81, 92,
94, 98, 107]. Jit et al. [30] performed multiple linear
regressions to estimate the proportion of hospitalisations
that was caused by influenza and provided details on the
goodness of fit (R2) of the model. They also indicated that
different regression models to estimate the proportion of
healthcare attendances related to influenza gave similar
outcomes, which provided internal validation of this input
into the health economic model. Purmonen et al. [98] used
different parametric survival models (Weibull, exponential,
log-logistic) to optimally fit the trace of the curves; how-
ever, how they decided on optimal fit was not reported.
Validation of the computerised model (category C) was
not found in any of the reviewed articles.
A total of 56 studies reported on validation of the
operational model (category D). Cross-validation of the
results (D2) was the validation technique found most often
in SI (57 %) as well as EBC (51 %). For example, Chit
et al. [22] performed an extensive comparison of the
number of influenza cases and various other clinical out-
comes with data published in a model from the Centers for
Disease Control and Prevention. Next to cross-validation,
validation of model outcomes to empirical data (D4) was
often found, namely in 20 studies. Three studies on SI
reported on independent validation (D4B) by validating the
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Fig. 2 Model validation performances of 53 studies on seasonal
influenza, as reported in publications, using the classification of the
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of studies. AdViSHE Assessment of the Validation Status of Health
Economic decision models
838 P. T. de Boer et al.
event against data from a national surveillance system or a
national registration agency [17, 25, 48]. Seventeen EBC
studies performed dependent validation (D4A) by com-
paring the results with data of the clinical trial the study
was based on. Two different EBC studies performed vali-
dation against independent data sources, namely against the
‘Adjuvant! Online’ prediction tool [84, 100], an online tool
used in the US to help oncologists estimate the risks of
mortality and side effects, given different clinical and
treatment scenarios [112]. Face validity testing of the
results (D1) was not reported in either of the disease areas,
and validation by using alternative input data (D3) was
found in one study [47]. This study used all parameters of a
similar study analyzing the same intervention in the same
country to compare the results.
Finally, two studies reported validation techniques that
were not categorised in the AdViSHE tool (Category E)
[64, 81]. Van Bellinghen et al. [64] performed double
programming by programming one cohort in another
software package, and Delea et al. [81] conducted an
extensive comparison of the input data compared with the
input data of other models, which might be regarded as
cross-validation of the input data.
3.4 Comments from Authors
We reached out twice to the corresponding authors to ask
whether, in practice, more validation efforts were per-
formed than those reported in the manuscript. We were
able to reach 77/94 corresponding authors, and of these we
received a total of ten responses. Three responding authors
informed us that they were not able to answer the enquiry
due to various reasons, such as no access to project files
anymore, study was conducted a long time ago, or current
workload was too high. Comments from the remaining
seven responding authors are shown below.
A first author response of an SI study included that,
additionally to what had been reported in the manuscript,
the complete model was double programmed (category E)
using a different software package, and results were com-
pared. When modifications were completed, the affected
modules were checked for face validity by another pro-
grammer (C1) and run against test data to ensure consis-
tency (D3). A second author response of an SI study
reported that face validity of the conceptual model (A1),
input data (B1) and model outcomes (D1) were assessed
internally and externally by two different panels of inde-
pendent researchers. Moreover, tests such as likelihood
ratio testing, Akaike information criterion (AIC), Bayesian
information criterion (BIC) and goodness of fit (B2) were
performed to select the optimum regression model to
determine the attributable fraction of influenza within
surveillance data of ‘influenza-like illness’. The authors
indicated that all input data have been varied outside their
ranges to detect coding errors (C2), and mentioned that this
was not reported in the manuscript since this was consid-
ered a natural part of model development. A third author
response of a SI study indicated that face validity of the
conceptual model (A1), input data (B1) and outcomes (D1)
were tested within the team containing clinical experts of
different fields. Moreover, the entire model was double
programmed (E). Additionally, the authors indicated that
validation of the computerised model (C) was not reported
as this was considered standard procedure.
Concerning EBC, a first author response mentioned that
the majority of the validation techniques that are found on
the AdViSHE tool were performed. The model was con-
structed to the standards of the National Institute for Health
and Care Excellence (NICE) guideline on technical apprai-
sal, which, according to the author, in turn implies a certain
standard of validation. A second author response indicated
that not all validation performances were reported due to a
very restrictive word limit of the journal and the audience of
the journal being mainly clinical. However, the structure of
the model was reviewed by clinical and health economic
experts within and outside the team (A1). In addition, a
quality control on input data (B1) and model programming
(C1) was performed by health economists not involved in
the original model design. Additionally, they attempted to
perform cross-validity of the model outcomes (D2) but were
unable to do so due to a lack of suitable comparison studies.
A third author responded that face validity of model struc-
ture (A1), input parameters (B1) and code checking (C1)
were performed, and that links between different submod-
ules were also tested (C4). A third author indicated that no
other additional validation efforts than those described in the
manuscript were performed.
4 Discussion
In this study, we assessed the reporting of model validation
efforts in the disease areas of SI and EBC within the period
2008 to 2014. Overall, reporting of model validation efforts
was found to be limited. Reviewing the papers systemati-
cally using the AdViSHE tool, demonstrated that 57 % of
the studies on SI and 71 % of the ECB models performed
at least one validation technique; however, only 9 and
37 % of studies on SI and EBC, respectively, performed
two or more validation techniques. A limited number of
author’s responses to our enquiry on model validation
efforts performed, indicated that, in practice, considerably
more validation techniques might be used than those
reported in the manuscripts, provided these few responders
are representative of the majority who did not reply to our
request for additional information.
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The most performed validation technique was cross-
validation of the model outcomes. A first explanation for
this might be that many general guidelines for writing
scientific papers state that the discussion section should
include a comparison of the study outcomes with the
existing literature (e.g. Hall [113]). Moreover, Eddy et al.
[114] specifically name cross-validation as one of the five
types of validation. Few reports were identified regarding
validation of the conceptual model, and no reports
regarding validation of the computerised model. As indi-
cated in two author responses, validation techniques such
as code checking and extreme value testing might be
regarded as implicit in the model development process and
were therefore not reported [12]. This might also partly
explain why face validity of the input data and results was
not often reported. Moreover, the peer-review process
before publication might be regarded by some authors as a
way of testing face validity. Another reason why little is
reported on validation of the conceptual model might be
that many studies of SI used a basic decision-tree model;
however, even in case of such simple models, validation
remains important. Conceptual model validation in that
case might possibly be even more important since the
choice of such a simple structure should be justified. A final
explanation might be that the word count or the (clinical)
audience of the journal might restrict authors on reporting
of validation efforts.
In addition to simply describing the conduct of valida-
tion, it may be useful for model users to report what was
done with the outcomes of the validation techniques. For
instance, did the authors make any changes to (parts of) the
model when faced with the validation outcomes? Such
outcomes may emphasize the importance of validation.
Unfortunately, none of the studies included in this review
reported this aspect of model validation.
The main difference between SI and EBC was found in
validation of the model outcomes by using empirical data.
Dependent validation of the model outcomes was found in
several studies of EBC but not in studies on SI. This may
be due to the nature of SI, which, as a communicable
disease, requires complex transmission dynamics and
should therefore be studied on a population level rather
than on a cohort level. For such dynamic SI models,
understanding disease transmission dynamics is complex
and the level of indirect protection caused by herd immu-
nity is dependent on vaccine uptake levels. This compli-
cates direct validation of model outcomes using
randomised clinical trials of influenza vaccines, further
enhanced by the variation of influenza activity by season or
nation, and that the vaccine might not match the prevalent
circulating strain. Independent validation of model out-
comes to incidence data of national healthcare registries
might therefore be more suitable compared with
randomised clinical trial data, although the quality of
influenza monitoring systems should then be taken into
account. Such monitoring systems might not always be
available in the studied countries.
We feel that simply mentioning that the model was
previously validated does not guarantee a high validation
status as new validation efforts are necessary when a model
is used in a different setting or with different data (a ‘new
application’). On the other hand, indicating that some
particular input data was not validated due to a lack of
suitable data sources was found to be useful for the reader
as they can distinguish which parts of the model include
high uncertainty [1]. Reporting that the model is validated
according to the guidelines of ISPOR–SMDM Task Force
on Good Research Practices–Modelling Studies [115], as
was reported by Van Bellinghen et al. [64], or to the
standards of the NICE, as was communicated through
author comments, is insufficient. Although such guidelines
give guidance on how model validation should be per-
formed [115], these guidelines are general in nature and it
is not clear which parts of validation have been performed,
how and by whom. Therefore, simply following these
guidelines does not guarantee that a model has a high
enough validation status for its purpose, nor that model
users can assess the validation status themselves.
Although a probabilistic sensitivity analysis is the most
important technique to demonstrate the uncertainty around
the model outcomes, using cost effectiveness acceptability
curves to demonstrate validity of the results [93, 95] does
not evaluate how accurately the model simulates what
occurs in reality. The model that was applied by the author
presenting with ten papers in our review was very similar
in nine of these studies; however, no cross-validation of the
conceptual model, or additional testing for variations, was
described in any of these papers. For instance, the model
type and structure were similar in most of the studies but
were adapted because of a different target group, per-
spective or vaccination strategy. Explanations on these
deviations or validation of their outcomes were lacking.
A positive example of reporting of model validation in
the eyes of the authors was the study of Campbell et al.
[77]. In this study, the underlying probability of a first
recurrent breast cancer was based on a regression-based
survival model that was externally validated against two
online prediction tools: Nottingham Prognostic Index and
Adjuvant! Online. A separate paper was devoted to the
estimation and validation of this model [116]. Moreover,
the web appendix contained an extensive report on external
validation of the model used to estimate health-related
quality-of-life during and after receiving chemotherapy.
Our finding that reporting of validation activities is
limited was confirmed by other studies. Carrasco et al. [10]
assessed the validation of dynamic transmission models
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evaluating the epidemiology of pandemic influenza, and
found that 16 % of the compartmental models and 22 % of
the agent-based models reported on validation. As valida-
tion of model outcomes might be more difficult in cases
where pandemic influenza is studied, reporting validation
efforts of conceptual models or model inputs might be
relatively more valuable. A study by Haji Ali Afzali et al.
[9] reviewed the validation performances of 81 studies on
therapeutic interventions for cardiovascular diseases, and
found that 73 % of the papers reported some form of model
performance. The most executed form of validity was
cross-validation (55 %), similar to this study. Reporting of
face validity (7 %), internal validity (12 %) and external
validity (16 %) was low. Although the review process was
carried out using a different checklist and was therefore not
completely comparable, these results at least support our
findings that cross-validation is the most reported valida-
tion procedure, and reporting of other validation efforts is
rare. Moreover, it demonstrates that limited validation
documentation is not restricted to the disease areas of SI
and EBC.
A strong point of this study is that we systematically
assessed model validation performances. We looked at two
disease areas, thereby covering a wider range of models
than previous studies. Moreover, compared with previous
studies analyzing reporting of validation efforts, we judged
validation not only by technique but also by model aspect:
conceptual model, input data, computerised model and the
model outcomes. This made our findings more specific on
which model aspects are generally validated and which are
not. A final strong point is that we provided authors an
opportunity to comment on whether more validation tech-
niques were performed than those reported in the paper,
which gave insight into the difference between perfor-
mance and reporting of validation.
A limitation of our study was that for most studies we
could only evaluate published validation efforts, rather than
actual validation efforts undertaken. Thus, these models
may have seemed less well-validated to the reader than
they actually were. Although the responses of contacted
authors of non-reported validation efforts were helpful, the
response rate was low. Moreover, authors who performed
more validation efforts might have been more aware of the
importance of model validation and therefore more eager to
respond to our enquiry. On the other hand, the poor
response rate might also indicate that authors do not record
which model validation tests were performed at the time
the analysis was carried out. This was illustrated by three
authors responses indicating that they were not able to
provide additional information because the analysis was
performed many years ago or because their current work-
load was too high. Next, we included ten papers on SI from
the same first author, which might have had an effect on the
total model validation performance within SI. Finally,
although our search algorithm was extensive, we still may
have missed publications that were not included in PubMed
or EmBase. However, the main focus of the current review
was to give insight into present practice with regard to
reporting of model validation, rather than a complete
comprehensive overview of model-based publications in
the fields of SI and EBC.
The main implication of our findings is that readers have
no structured insight into the validation status of health
economic models, which makes it difficult for them to
evaluate the credibility of the model and its outcomes. In
order to prevent making wrong decisions due to improper
model validation status, readers might therefore be forced
to perform validity checks themselves, which is highly
inefficient. To date, we are not aware of any studies that
have looked into the impact of the model’s validation status
on the correctness of the model outcomes; however, we are
aware of a case in The Netherlands in which the validation
status of the health economic model can have a decisive
effect on the reimbursement status of a drug. In this case, a
vaccine against human papillomavirus was rejected for
reimbursement because of a lack of model transparency
and non-face-valid model inputs and model outcomes [117,
118].
Based on our results, we have several recommendations.
First, better attention should be given to validation efforts
in scientific publications. A more systematic use of model
reporting guidelines might be useful [119, 120], possibly
aided by reporting tools specifically aimed at validation
efforts, such as AdViSHE [15]. In order to circumvent
space limitations, inclusion of a small summary on model
validation techniques in the Methods and Result sections
would be desirable, in combination with a full model val-
idation report in online appendices. Moreover, validation is
important for all published health economic models, even
if the model was validated for an earlier purpose. In
addition, the choice of validation techniques reported
deserves more attention and should be less guided by
general publication guidelines, which now seem to imply
undue attention for cross-validation only. Finally, it will be
interesting to see whether the reporting of validation efforts
will improve in time. A similar publication in a few years’
time will be very welcome.
5 Conclusions
Although validation is deemed important by many
researchers, this is not reflected in the reporting habits of
health economic modelling studies. A limited number of
studies reported on model validation efforts, although good
examples were identified. This lack of transparency might
Reporting of Validation Efforts of Health Economic Decision Models 841
reduce the credibility of study outcomes and hamper
decision makers in interpreting and translating these study
outcomes to policy decisions. Since authors have indicated
that much more is undertaken than is reported, there is
room for quick improvement of the reporting practices if
stakeholders such as journals, editors and policy makers
start explicitly requesting the results of the validation
efforts. Therefore, systematic reporting of validation
efforts would be desirable to further enhance decision
makers’ confidence in health economic models and their
outcomes.
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